Aratana Therapeutics Company Profile (NASDAQ:PETX)

Analyst Ratings

Consensus Ratings for Aratana Therapeutics (NASDAQ:PETX) (?)
Ratings Breakdown: 1 Hold Rating(s), 7 Buy Rating(s)
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $12.29 (88.43% upside)

Analysts' Ratings History for Aratana Therapeutics (NASDAQ:PETX)
Show:
DateFirmActionRatingPrice TargetActions
7/17/2016Lake Street CapitalReiterated RatingBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/26/2016William BlairReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/2/2016Credit Suisse Group AGReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/2/2016Jefferies GroupReiterated RatingBuy$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/16/2016Craig HallumLower Price TargetHold$11.00 -> $7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/16/2016Stifel NicolausLower Price TargetBuy$12.00 -> $11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/2/2015Barclays PLCReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/4/2015Piper Jaffray Cos.Reiterated RatingOverweight$25.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2015JMP SecuritiesSet Price TargetBuy$38.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2015Bank of America Corp.Boost Price Target$26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2014 forward)

Earnings

Earnings History for Aratana Therapeutics (NASDAQ:PETX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/5/2016Q116($0.42)($0.52)$0.13 million$0.17 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/14/2016Q415($0.41)($0.37)$0.21 million$0.06 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.39)($1.58)$0.21 million$0.23 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q2($0.38)($0.23)$0.18 million$0.23 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015($0.40)($0.26)$0.30 million$0.16 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2015Q315($0.35)($0.30)$0.10 million$0.25 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q315($0.41)($0.35)$0.25 million$0.43 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014Q215($0.36)($0.32)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2014Q115($0.35)($0.34)$0.09 million$0.18 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/13/2014Q414($0.21)$0.40ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2013Q3($0.20)($0.22)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2013Q2($10.21)($4.62)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aratana Therapeutics (NASDAQ:PETX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.42)($0.40)($0.41)
Q2 20162($0.43)($0.41)($0.42)
Q3 20163($0.43)($0.39)($0.41)
Q4 20162($0.40)($0.34)($0.37)
Q1 20181($0.19)($0.19)($0.19)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Aratana Therapeutics (NASDAQ:PETX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Aratana Therapeutics (NASDAQ:PETX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/28/2016Julia A StephanusInsiderSell30,000$6.25$187,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2016Peter Steven StCEOSell100,000$6.26$626,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2016Ernst HeinenInsiderSell15,000$6.72$100,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/1/2016Craig A ToomanCFOSell2,806$3.36$9,428.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/9/2015Craig A ToomanCFOSell3,620$7.52$27,222.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/2/2015Craig A ToomanCFOSell3,250$8.06$26,195.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2015Ernst HeinenInsiderSell15,000$17.06$255,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/27/2015Linda RhodesInsiderSell15,000$15.00$225,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/6/2015Linda RhodesInsiderSell20,000$20.00$400,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/6/2015Vort John VanderDirectorSell6,137$20.01$122,801.37View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/13/2015Julia A StephanusInsiderSell6,300$19.00$119,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/13/2015Peter Steven StCEOSell75,000$19.23$1,442,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/22/2014Linda RhodesInsiderSell10,000$18.00$180,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/3/2014Julia A StephanusInsiderSell2,000$17.33$34,660.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014Linda RhodesInsiderSell10,000$16.00$160,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2014Linda RhodesInsiderSell4,626$15.00$69,390.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2014Julia A StephanusInsiderSell8,000$13.90$111,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2014Peter Steven StCEOSell25,000$13.47$336,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/5/2014Ernst HeinenInsiderSell10,000$13.42$134,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/3/2014Ronald MeeusenDirectorSell500,000$19.00$9,500,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/2/2013Julia A StephanusInsiderBuy2,000$6.00$12,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/2/2013Peter Steven StCEOBuy8,333$6.00$49,998.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/2/2013Ventures Ix L.P. AvalonMajor ShareholderBuy500,000$6.00$3,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Aratana Therapeutics (NASDAQ:PETX)
DateHeadline
07/24/16 09:56 AMCan Aratana Therapeutics, Inc. (NASDAQ:PETX) Surprise Analysts this Quarter? - Investor Newswire
07/23/16 05:18 PMAccounts Payable For Aratana Therapeutics, Inc. (NASDAQ:PETX) Stood At $6.38 - RealistInvestor.com
07/22/16 05:40 PMAratana Therapeutics Inc (NASDAQ:PETX) Price Volatility Hits An Elevated Level - CML News
07/21/16 06:06 PMEarnings Focus and Crowd Sourced Sentiment Review for Aratana Therapeutics, Inc. (NASDAQ:PETX) - TGP
07/21/16 06:06 PMStock Focus: Following Analyst Expectations on Shares of Aratana Therapeutics, Inc. (NASDAQ:PETX) - TGP
07/20/16 08:39 AMHeightened Volatility Spotted on Shares of: Aratana Therapeutics, Inc. (NASDAQ:PETX) - Engelwood Daily
07/19/16 05:55 AMAwm Investment Company INC Increased Aratana Therapeutics INC (NASDAQ:PETX) by $3.76 Million as Shares Rose - Press Telegraph
07/18/16 05:54 PMNew Broker Ratings For Aratana Therapeutics, Inc. (PETX) - FTSE News
07/18/16 05:54 PMAratana Therapeutics Incorporated (NASDAQ:PETX) Shorted Shares Increased 6.12% After Market Selling - Consumer Eagle
07/18/16 05:54 PMIs $18 Price Target Attainable For Aratana Therapeutics, Inc. (NASDAQ:PETX)? - Investor Newswire
07/17/16 09:58 AMShares Moving Down on the Week: Aratana Therapeutics, Inc. (NASDAQ:PETX) - Engelwood Daily
07/16/16 05:17 PMAratana Therapeutics, Inc. (NASDAQ:PETX) Quarterly Accounts Payable At $6.38 Millions - RealistInvestor.com
07/16/16 09:02 AMAnalyst Target and Average Rating Watch: Aratana Therapeutics, Inc. (NASDAQ:PETX) - Press Telegraph
07/15/16 04:48 PMWeakness in Aratana Shares An 'Excellent' Entry Point
07/15/16 10:50 AMIs Selling Aratana Therapeutics Inc Here a Winning Strategy? - Consumer Eagle
07/14/16 09:23 AMAratana Therapeutics : Appoints Chief Operating Officer
07/13/16 03:05 PMAratana Therapeutics to Report Second Quarter 2016 Financial Results - [PR Newswire] - LEAWOOD, Kan., July 13, 2016 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical ...
07/11/16 10:28 AMStock Rating Watch and Earnings Insight for Aratana Therapeutics, Inc. (NASDAQ:PETX) - Press Telegraph
07/09/16 08:55 AMAratana Therapeutics Incorporated (NASDAQ:PETX) Short Interest Increased By 6.12% - Engelwood Daily
07/08/16 05:47 PMHeightened Volatility Check on: Aratana Therapeutics, Inc. (NASDAQ:PETX) - Engelwood Daily
07/08/16 05:47 PMCan Aratana Therapeutics, Inc. (NASDAQ:PETX) Improve on the Earnings Front? - Engelwood Daily
07/08/16 05:47 PMCompany Stock Focus for Aratana Therapeutics, Inc. (NASDAQ:PETX): Which Way Will Shares Head? - Press Telegraph
07/04/16 05:01 PMAratana Therapeutics, Inc. (NASDAQ:PETX) Expected to Reach Highs Of $18 - Investor Newswire
07/04/16 05:01 PMShare Performance Recap for: Aratana Therapeutics, Inc. (NASDAQ:PETX) - Press Telegraph
07/01/16 05:49 PMUpdate on Stock Volatility for: Aratana Therapeutics, Inc. (NASDAQ:PETX) - Engelwood Daily
07/01/16 05:49 PMCould Aratana Therapeutics Inc Decline After Today's Huge Increase? - Press Telegraph
07/01/16 05:49 PMAratana Therapeutics (PETX) Names COO - StreetInsider.com
07/01/16 05:33 PMETF’s with exposure to Aratana Therapeutics, Inc. : July 1, 2016 -
06/30/16 11:50 AMIt's a hat trick: Aratana files for third FDA approval -
06/30/16 08:40 AMAratana Therapeutics Files for FDA Approval of NOCITA® (bupivacaine liposome injectable suspension)
06/29/16 05:43 PMAratana Therapeutics (PETX) Names COO
06/29/16 04:30 PMAratana Therapeutics Appoints Chief Operating Officer - [PR Newswire] - LEAWOOD, Kan., June 29, 2016 /PRNewswire/ -- Aratana Therapeutics, Inc. (PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, announced today that the Company has appointed Brent A. Standridge Chief Operating Officer, a new position within Aratana. "As Aratana prepares to launch its recently approved products, this new executive role emphasizes the company's commitment to sales operations and distribution," explains Steven St. Peter, M.D., President and Chief Executive Officer of Aratana.
06/29/16 08:36 AMAratana Therapeutics, Inc. (NASDAQ:PETX) Company Rating and Target Watch - Telanagana Press
06/28/16 10:39 AMShare Update and Earnings Review for Aratana Therapeutics, Inc. (NASDAQ:PETX) - Press Telegraph
06/28/16 10:39 AMAratana Therapeutics Incorporated (NASDAQ:PETX) Shorted Shares Increased By 6.12% - Engelwood Daily
06/28/16 10:39 AMStrong Sell Calls Recommendations For Aratana Therapeutics, Inc. (NASDAQ:PETX) At 0 - Investor Newswire
06/24/16 05:51 PMCovering the Bases on Aratana Therapeutics, Inc. (NASDAQ:PETX): Where is the Stock Going? - Press Telegraph
06/24/16 05:51 PMAratana Therapeutics, Inc. (NASDAQ:PETX) Earnings Glance and Target Price Review - Engelwood Daily
06/23/16 06:22 PMStock Buzz: Aratana Therapeutics, Inc. (NASDAQ:PETX) - iStreetWire
06/23/16 06:22 PMAratana Therapeutics, Inc. (PETX) Current Analyst Ratings - Fiscal Standard
06/21/16 05:19 PMStrong Buy Calls Count For Aratana Therapeutics, Inc. (NASDAQ:PETX) At 5 - Investor Newswire
06/10/16 06:03 PMWill Aratana Therapeutics, Inc. (NASDAQ:PETX) Surprise Analysts? - Investor Newswire
06/08/16 06:12 PMARATANA THERAPEUTICS INC. (NASDAQ:PETX) Financial Condition Compared to S&P 500 - CML News
06/05/16 05:46 PMAratana Therapeutics, Inc. (PETX) Broker Price Targets For The Coming Week - Share Trading News
06/02/16 06:11 PMAratana Therapeutics, Inc. (NASDAQ:PETX) Change In Inventory At $-0.879 Millions - RealistInvestor.com - Aratana Therapeutics, Inc. (NASDAQ:PETX) Change In Inventory At $-0.879 MillionsRealistInvestor.comAratana Therapeutics, Inc. (NASDAQ:PETX) accounts payable was $1.4 millions for the fiscal closed 2015-12-31. For the quarter ended 2015-12-31 it was $1.4 millions. At the end of the year 2015-12-31, the deviation in accounts payable was $-0.117 ...
06/02/16 06:11 PMAratana Therapeutics (PETX) Is Strong On High Volume Today - TheStreet.com - TheStreet.comAratana Therapeutics (PETX) Is Strong On High Volume TodayTheStreet.comAratana Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on the licensing, development, and commercialization of biopharmaceutical products for the companion animals worldwide. Currently there are 5 analysts that rate Aratana ...and more »
06/02/16 08:46 AMAratana Therapeutics, Inc. (PETX) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News - Aratana Therapeutics, Inc. (PETX) Do Brokers Advise Buy, Sell Or Hold?Share Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Aratana Therapeutics, Inc. (PETX). The latest reports which are currently in issue on Thursday 2nd of June state 0 analysts have a rating of “strong buy”, 0 analysts ...and more »
06/02/16 08:23 AMAratana Therapeutics Receives CMC Technical Section Complete Letter for Post-Operative Pain Therapeutic - [PR Newswire] - LEAWOOD, Kan., June 2, 2016 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical ...
06/01/16 06:17 PMAratana Therapeutics, Inc. (NASDAQ:PETX) Quarterly EPS Estimate At $-0.39 - Investor Newswire - Aratana Therapeutics, Inc. (NASDAQ:PETX) Quarterly EPS Estimate At $-0.39Investor NewswireFirst Call stated that Aratana Therapeutics, Inc. (NASDAQ:PETX) can touch $12.33 in coming one year. For the next quarter, the per-share earnings target is $-0.39 and for ongoing fiscal at $-1.08. EPS target for next year is $-1.05 versus the mean EPS ...and more »
06/01/16 08:42 AMAratana Therapeutics Inc. (PETX) Jumps 9.98% on May 30 - Equities.com - Aratana Therapeutics Inc. (PETX) Jumps 9.98% on May 30Equities.comAratana Therapeutics Inc. (PETX) was among the biggest gainers on the Russell 2000 for Monday May 30 as the stock popped 9.98% to $6.83, representing a gain of $0.62 per share. Some 939,224 shares traded hands on 4,850 trades, compared with an ...and more »

Social

About Aratana Therapeutics

Aratana Therapeutics logoAratana Therapeutics, Inc. is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company has licensed and is developing more than 18 therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target serious medical conditions, such as pain and inflammation, stimulation of appetite, cancer and other serious diseases for dogs and cats. These product candidates are in various stages of development for the treatment of cats or dogs, or both. The Company's target indications include pain and inflammation associated with osteoarthritis, inappetence, post-operative pain, lymphoma, osteosarcoma, atopic dermatitis, ocular herpes and feline immunodeficiency virus. The Company's most advanced products from a development and commercialization perspective, AT-004 and AT-005, are monoclonal antibodies (MAbs) for treating lymphoma in dogs.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: PETX
  • CUSIP:
Key Metrics:
  • Previous Close: $6.52
  • 50 Day Moving Average: $6.61
  • 200 Day Moving Average: $5.30
  • P/E Ratio: N/A
  • P/E Growth: -0.43
  • Market Cap: $230.46M
  • Beta: 3.78
  • Current Year EPS Consensus Estimate: $-1.7 EPS
  • Next Year EPS Consensus Estimate: $-1.04 EPS
Additional Links:
Aratana Therapeutics (NASDAQ:PETX) Chart for Monday, July, 25, 2016